login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
NUREXONE BIOLOGIC INC (NRX.CA) Stock News
Canada
- TSX-V:NRX -
CA67059R1091
-
Common Stock
0.7
CAD
-0.01 (-1.41%)
Last: 11/17/2025, 7:00:00 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
NRX.CA Latest News, Press Relases and Analysis
All
Press Releases
5 days ago - By: NurExone Biologic Inc
NurExone Secures over C$3.18 Million Through Accelerated Warrant Exercises
14 days ago - By: NurExone Biologic Inc
NurExone Accepted into ARMI’s BioFab Startup Lab Strengthening U.S Position in Regenerative Manufacturing
a month ago - By: NurExone Biologic Inc
NurExone Invited Presenter at Precision EV Forum in Cambridge, UK
a month ago - By: NurExone Biologic Inc
NurExone Demonstrates Reproducible, Dose-Dependent Vision Recovery in Preclinical Glaucoma Model
2 months ago - By: NurExone Biologic Inc
NurExone Planning to Establish First U.S. Commercial Manufacturing Facility in Indiana
2 months ago - By: NurExone Biologic Inc
NurExone Biologic Announces Corporate Updates including Israel Patent Grant and Private Placement Closing
2 months ago - By: NurExone Biologic Inc
NurExone Receives U.S. Patent Allowance for Exosome Manufacturing, Strengthening Supply Chain Readiness
3 months ago - By: NurExone Biologic Inc
NurExone Biologic Inc. Announces Second Quarter 2025 Financial Results
3 months ago - By: NurExone Biologic Inc
NurExone Biologic Announces Preclinical Evidence of Structural Repair in Injured Spinal Cord Tissue following ExoPTEN Treatment
3 months ago - By: NurExone Biologic Inc
NurExone’s Exosomes Show Stronger Healing Potential Than Industry Standard
4 months ago - By: NurExone Biologic Inc
NurExone Biologic Finalist in Falling Walls Venture 2025 Global Platform Showcasing The World’s Most Promising Science-Based Start-Ups
4 months ago - By: NurExone Biologic Inc
New ExoPTEN Preclinical Study Indicates Significant Improvement in Walking Quality in Spinal Cord Injury Model
5 months ago - By: NurExone Biologic Inc
NurExone Advances U.S. Growth Strategy with Acceptance into Prestigious ARMI HealthTech Hub Accelerator and Provides Corporate Update
6 months ago - By: NurExone Biologic Inc
NurExone Strengthens Path to Clinical Trials for ExoPTEN with New Manufacturing Process Validation
6 months ago - By: NurExone Biologic Inc
NurExone Announces Clinical Trial Plans for Acute Spinal Cord Injury Therapy at Annual Meeting of American Spinal Injury Association
6 months ago - By: NurExone Biologic Inc
NurExone Biologic Inc. Announces First Quarter 2025 Financial Results and Provides Corporate Update
6 months ago - By: NurExone Biologic Inc
NurExone Advances Vision Restoration Strategy with Preclinical Data Presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2025
7 months ago - By: NurExone Biologic Inc
NurExone Expands European Engagement with Investor Events in Germany and Switzerland
7 months ago - By: NurExone Biologic Inc
NurExone to Showcase Breakthrough in Facial Nerve Regeneration at ISEV 2025
7 months ago - By: NurExone Biologic Inc
NurExone Appoints Biotech Industry Leader - Jacob Licht to Lead U.S. Operations and Exo-Top Manufacturing Expansion and Completes Continuance into Ontario
7 months ago - By: NurExone Biologic Inc
NurExone Biologic Inc. Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update
8 months ago - By: NurExone Biologic Inc
NurExone Biologic Announces U.S. Uplisting Intention and Closes C$2.3 Million Private Placement
8 months ago - By: NurExone Biologic Inc
ExoPTEN Preclinical Study Demonstrates Significant Potential for Enhancing Motor Function, Blood Flow, and Spinal Cord Injury Recovery
9 months ago - By: NurExone Biologic Inc
NurExone Biologic to Present at MIXiii 2025; Professor Michael Belkin, Head of NurExone Ophthalmology Project, to Receive Lifetime Achievement Award
9 months ago - By: NurExone Biologic Inc
NurExone Biologic Recognized as a 2025 TSX Venture 50™ Top Performing Stock
9 months ago - By: NurExone Biologic Inc
NurExone Biologic Continues Expansion of U.S. Presence and Awareness with Prestigious Conference Presentation
10 months ago - By: NurExone Biologic Inc
NurExone Forms Exo-Top Inc. in the U.S. for Exosome Manufacture and Commercialization
10 months ago - By: NurExone Biologic Inc
NurExone Secures C$1.2 Million through Warrant Exercises and Completion of Private Placement and Appoints New R&D Director
10 months ago - By: NurExone Biologic Inc
NurExone Biologic Secures Master Cell Bank
a year ago - By: NurExone Biologic Inc
NurExone Announces Promising Preclinical Results in Restoring Vision After Optic Nerve Damage
a year ago - By: NurExone Biologic Inc
NurExone Reports Third Quarter 2024 Financial Results and Provides Corporate Update
a year ago - By: NurExone Biologic Inc
NurExone Biologic Secures EMA Orphan Status for ExoPTEN in Spinal Cord Injury, Accelerating Pathway to European Markets
a year ago - By: NurExone Biologic Inc
NurExone Biologic Closes Final Tranche of Non-Brokered Private Placement and Provides Corporate Update
a year ago - By: NurExone Biologic Inc
NurExone’s Regenerative Medicine Therapies To Be Recognized at Fall Conferences in the USA
a year ago - By: NurExone Biologic Inc
NurExone Biologic Announces Private Placement of up to $2M and Closes First Tranche for $1.61M
a year ago - By: NurExone Biologic Inc
NurExone Biologic Extends Global Reach with Presentations at Industry-Leading Conferences
a year ago - By: NurExone Biologic Inc
NurExone Demonstrates Extended Therapeutic Window of ExoPTEN Post Spinal-Cord Injury in Preclinical Study
a year ago - By: NurExone Biologic Inc
NurExone Reports Second Quarter 2024 Financial Results and Provides Corporate Update
a year ago - By: NurExone Biologic Inc
NurExone Biologic Invited to Present Groundbreaking ExoPTEN Therapy at Prestigious September Conferences
Please enable JavaScript to continue using this application.